| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0025-7753(17)30623-1 |
| P698 | PubMed publication ID | 28760223 |
| P2093 | author name string | Gabriel Cuatrecasas | |
| Fernando Goñi-Goicoechea | |||
| P2860 | cites work | Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence | Q26752703 |
| SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis | Q28076978 | ||
| The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus | Q33888236 | ||
| Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus | Q33949927 | ||
| The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials | Q35141884 | ||
| Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis | Q35157497 | ||
| Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study | Q35587416 | ||
| Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight. | Q36357997 | ||
| POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. | Q38541561 | ||
| Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study | Q39821148 | ||
| Clinical implications of canagliflozin treatment in patients with type 2 diabetes | Q41476579 | ||
| Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. | Q41641012 | ||
| Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial | Q44452805 | ||
| Effect of a multifactorial intervention on mortality in type 2 diabetes | Q46767642 | ||
| Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years | Q47871792 | ||
| Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC. | Q50437223 | ||
| [Control of type 2 diabetes mellitus in Spain today: identification of the main obstacles in daily clinical practice]. | Q51237063 | ||
| Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Q51359456 | ||
| Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study. | Q53504770 | ||
| [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain]. | Q53647314 | ||
| Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion | Q57303412 | ||
| P921 | main subject | glycobiology | Q899224 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 30-34 | |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | Medicina clínica | Q26854009 |
| P1476 | title | Clinical profile of patients with type 2 diabetes mellitus treated with sodium- glucose cotransporter-2 inhibitors and experience in real-world clinical practice in Spain | |
| P478 | volume | 147 Suppl 1 |
Search more.